Pulse Biosciences opened lower at $56.59, compared with its previous close of $56.98. In the last trading session, the stock traded between $53.50 and $56.81. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Pulse Biosciences is now worth
$ 241.96
Giving a profit of
$ 141.96 (141.96%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-4.77 (-8.36%)
Day High
$56.81
Day Low
$53.50
Day Open
$56.59
Prev Close
$56.98
Volume
2,90,154
1W Return
-8.29%
1M Return
-0.47%
3M Return
17.57%
6M Return
173.66%
1Y Return
240.82%
Market Cap ($ Mn)
3,840
PE Ratio
-
PB Ratio
33.86
PEG Ratio
-
ROE
-71.19%
ROCE
-70.64%
EPS (TTM)
$-0.31
1 Week
-8.29%
1 Month
-0.47%
3 Months
17.57%
6 Months
173.66%
9 Months
106.79%
Canaccord Genuity raises Pulse Biosciences price target to $74
Canaccord Genuity raises price target to $74. Previous price target was set at $58. Analyst William Plovanic maintains Buy rating.
6 days agoPulse Biosciences reports 86% volume reduction in thyroid nodule study
86% of patients achieved at least 50% nodule volume reduction at six months. Median nodule volume reduction reached 72%, with most reduction evident by one month. ThyPRO-39 Overall Quality of Life Impact score improved 78% from baseline. Neck pressure or fullness fully resolved in 82% of patients who had it at baseline. No serious adverse events were reported in the interim dataset.
6 days agoPulse Biosciences Q3FY26 Results: Cash $189M, AF trial enrollment complete
Completed NanoPulse AF pivotal study enrollment three months ahead of schedule. Ended quarter with $189 million in cash and marketable securities. GAAP net loss widened to $23.1 million from $19.4 million YoY. Revenue increased to $395,000 from $86,000 in prior-year period. Raised over $150 million via ATM programs since May with low dilution.
7 days agoPulse Biosciences partners with Clayman Thyroid Center in Tampa
Partnership covers commercial use of nPulse Vybrance System at Clayman Thyroid Center. Center is the sole provider of nPFA technology for benign thyroid nodules in Tampa Bay Area. Collaboration includes clinical data generation on nsPFA energy usage.
29 days agoPulse Biosciences grants options for 5,700 shares to new hires
Granted options for 5,700 shares to two new employees. Exercise price fixed at $49.98 per share. Awards vest over four years with annual tranches. Grants issued under Nasdaq Listing Rule 5635(c)(4).
1mo agoPulse Biosciences completes PRECISE-BTN enrollment for thyroid study
Pulse Biosciences completes enrollment of 100 patients in the PRECISE-BTN study. Enrollment doubled from the original 50-patient design over approximately 12 months. First patient completed the final 12-month follow-up visit in August. Study covers three U.S. sites including NYU Langone and Weill Cornell Medicine.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Pulse Biosciences is now worth
$ 241.96
Giving a profit of
$ 141.96 (141.96%)
Note: Past profits do not guarantee future returns.
